PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Alliance Foundation Trials phase III PATINA study shows promise for patients with HR+, HER2+ metastatic breast cancer

Palbociclib is the first CDK4/6 inhibitor to show benefit in a large phase III trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy

2024-12-12
(Press-News.org) Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE®) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). In the study, which is sponsored by AFT, median PFS was 44.3 months (95% CI: 32.4-60.9) for patients treated with palbociclib in combination with anti-HER2 therapy (trastuzumab or trastuzumab plus pertuzumab) and endocrine therapy and 29.1 months (95% CI: 23.3-38.6) for patients treated with anti-HER2 therapy and endocrine therapy alone [HR: 0.74 (95% CI, 0.58-0.94; unstratified 1-sided p= 0.0074]. This represents an extension in median PFS of more than 15 months. Overall survival, a secondary endpoint, was not yet mature at the time of the analysis. These results are being presented during a late-breaking oral session (Abstract GS2-12) and highlighted in the press program at the 47th San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.

 “PATINA is the first large phase III study to show the benefit of CDK4/6 inhibition in HR-positive, HER2-positive metastatic breast cancer,” said Otto Metzger, MD, Principal Investigator of the trial for Alliance Foundation Trials and Medical Oncologist at the Dana-Farber Cancer Institute. “These results support the potential of this maintenance treatment to slow disease progression and improve clinical outcomes in this patient population.”

Approximately 10% of all breast cancers are HR+, HER2+ [1], which is sometimes referred to as double-positive or triple-positive breast cancer. Despite advances in treatment, the development of resistance to anti-HER2 and endocrine therapy is common, and novel therapeutic approaches are needed for HR+, HER2+ MBC.[2] Palbociclib is not currently indicated for HR+, HER2+ MBC.

“IBRANCE, the first CDK4/6 inhibitor, revolutionized the treatment of HR-positive, HER2-negative metastatic breast cancer, and has been prescribed to over 773,000 patients since its initial approval in 2015," said Roger Dansey, MD, Chief Development Officer, Oncology, Pfizer. "These results demonstrate that the addition of IBRANCE to standard of care shows promise as maintenance therapy in HR-positive, HER2-positive disease. This trial underscores Pfizer’s leadership in addressing the needs of people with breast cancer, and we look forward to discussing the results with regulatory authorities.”

The safety and tolerability of palbociclib in the PATINA study was consistent with its known safety profile in HR+, HER2- MBC, and no new safety signals were identified. The most common adverse events observed with palbociclib were hematologic toxicities, such as neutropenia and leukopenia. Non-hematologic adverse events included fatigue, stomatitis, and diarrhea, which were generally mild to moderate in severity.

Since its initial regulatory approval in 2015, palbociclib continues to be a standard of care first-line treatment for HR+, HER2- MBC and has been approved in more than 108 countries. Pfizer plans to share the results from PATINA with regulatory authorities.

About the PATINA Trial
PATINA (AFT-38) is a randomized, open-label phase III study to evaluate the efficacy and safety of palbociclib (IBRANCE®) in combination with anti-HER2 therapy and endocrine therapy compared to anti-HER2 therapy and endocrine therapy alone as a first-line maintenance therapy (following induction chemotherapy treatment) for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). While Pfizer is providing funding support for the trial, PATINA is sponsored by Alliance Foundation Trials, LLC (AFT) in collaboration with six international cancer research groups in the U.S., Germany, Italy, Spain, Australia, and New Zealand.

Study participants who were previously treated with anti-HER2 therapy were randomized to receive palbociclib, in addition to anti-HER2 therapy and endocrine therapy (n=261), or anti-HER2 therapy and endocrine therapy alone (n=257). The primary endpoint is progression-free survival (PFS) as assessed by the investigator. Overall survival is a secondary endpoint.  

[1] National Cancer Institute. Cancer Stat Facts: Female Breast Cancer Subtypes. https://seer.cancer.gov/statfacts/html/breast-subtypes.html#:~:text=Percent%20of%20Female,Unknown%20(6%25). Accessed December 2024.

[2] Nature. Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

END


ELSE PRESS RELEASES FROM THIS DATE:

COMET trial finds quality of life similar among patients with low- risk DCIS whether they received active monitoring or surgery

2024-12-12
SAN ANTONIO – Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024. The results of this study were simultaneously published in JAMA Oncology. “Active monitoring” is a strategy in which patients are monitored closely, with surgery reserved for those patients who ...

Adjuvant tamoxifen may reduce recurrence risk for patients with ‘good-risk’ DCIS who forgo radiation

2024-12-12
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024. “Good-risk” DCIS was defined as grade 1 or 2, 2.5 cm or smaller, and having clear surgical margins of 3 mm or greater. Current guidelines from the National Comprehensive Cancer Network (NCCN) advise that patients who undergo breast-conserving surgery after a diagnosis ...

COMET trial finds active monitoring is a viable option for some patients with low-risk DCIS

2024-12-12
SAN ANTONIO – Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024. The results of this study were simultaneously published in JAMA. “Active monitoring” is a strategy in which patients are monitored closely, with surgery reserved for those patients who develop cancer. A steady increase ...

Most patients with intermediate-risk breast cancer may safely avoid chest wall irradiation after mastectomy

2024-12-12
SAN ANTONIO – Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they underwent chest wall irradiation (CWI) after mastectomy, according to results from the BIG 2-04 MRC SUPREMO clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024. “While post-mastectomy CWI is the standard of care for most patients with early-stage breast cancer who have four or more positive axillary lymph nodes, its role in patients with fewer positive lymph nodes or node-negative disease remains controversial,” ...

Active monitoring with or without endocrine therapy for low-risk ductal carcinoma in situ

2024-12-12
About The Study: Women with low-risk ductal carcinoma in situ randomized to active monitoring did not have a higher rate of invasive cancer in the same breast at 2 years compared with those randomized to guideline-concordant care.  Corresponding Author: To contact the corresponding author, E. Shelley Hwang, MD, MPH, email shelley.hwang@duke.edu. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jama.2024.26698) Editor’s Note: Please ...

Patient-reported outcomes for low-risk ductal carcinoma in situ

2024-12-12
About The Study: In this prespecified secondary analysis of the Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) prospective randomized trial, the overall lived experience of women randomized to undergo active monitoring for low-risk ductal carcinoma in situ was similar to that of women randomized to guideline-concordant care during the 2 years following diagnosis.  Corresponding Author: To contact the corresponding author, Ann H. Partridge, MD, MPH, email ann_partridge@dfci.harvard.edu. To access the embargoed study: Visit our For The Media website ...

Women born prematurely are at greater risk of committing suicide

Women born prematurely are at greater risk of committing suicide
2024-12-12
Not only are they the smallest among us, premature children also face health and life challenges that make them the most vulnerable. Generally speaking, they have a slightly higher risk of mortality due to illness. It is now apparent that they also have a higher risk of unexpected death from so-called external causes: road traffic accidents, substance abuse and suicide. This has been revealed in a major Nordic study led by Professor Kari Risnes from the Faculty of Medicine and Health Sciences at the Norwegian University of Science and Technology (NTNU). The researchers have analyzed birth data and causes of death for nearly 37,000 individuals aged between 15 ...

Bovhyaluronidaze azoximer significantly reduces exercise intolerance in patients with long-term pulmonary sequelae of COVID-19

2024-12-12
Petrovax announced today the positive results from “Long-CoV-III-21,” a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19. Bovhyaluronidase azoximer, marketed under the brand name Longidaza, is a polymer-conjugated hyaluronidase with an extended half-life. The study drug and placebo were administered for 71 days, with an observation period extending to Day 180. Longidaza demonstrated a statistically significant 62% reduction in the proportion of patients with exertional desaturation ...

New insights into the evolution and paleoecology of mosasaurs: most comprehensive study to date

New insights into the evolution and paleoecology of mosasaurs: most comprehensive study to date
2024-12-12
Mosasaurs are extinct marine lizards, spectacular examples of which were first discovered in 1766 near Maastricht in the Netherlands, fueling the rise of the field of vertebrate palaeontology (the study of fossil remains of animals with backbones). Palaeontologist Michael Polcyn presented the most comprehensive study to date on the early evolution and ecology of these extinct marine reptiles. On 16 December, Polcyn will receive his PhD from Utrecht University for his research into the evolution of the mosasaurs. "Mosasaurs are a textbook example of macroevolution, ...

New insights into brain mechanisms underlying empathy

New insights into brain mechanisms underlying empathy
2024-12-12
Genova (Italy), 12th December 2024 – A specific brain mechanism modulates how animals respond empathetically to others’ emotions. This is the latest finding from the research unit Genetics of Cognition, led by Francesco Papaleo, Principal Investigator at the Istituto Italiano di Tecnologia (IIT - Italian Institute of Technology) and affiliated with IRCCS Ospedale Policlinico San Martino in Genova. The study, recently published in Nature Neuroscience, provides new insights into psychiatric ...

LAST 30 PRESS RELEASES:

New study reveals how reduced rainfall threatens plant diversity

New study reveals optimized in vitro fertilization techniques to boost coral restoration efforts in the Caribbean

No evidence that maternal sickness during pregnancy causes autism

Healthy gut bacteria that feed on sugar analyzed for the first time

240-year-old drug could save UK National Health Service £100 million a year treating common heart rhythm disorder

Detections of poliovirus in sewage samples require enhanced routine and catch-up vaccination and increased surveillance, according to ECDC report

Scientists unlock ice-repelling secrets of polar bear fur for sustainable anti-freezing solutions 

Ear muscle we thought humans didn’t use — except for wiggling our ears — actually activates when people listen hard

COVID-19 pandemic drove significant rise in patients choosing to leave ERs before medically recommended

Burn grasslands to maintain them: What is good for biodiversity?

Ventilation in hospitals could cause viruses to spread further

New study finds high concentrations of plastics in the placentae of infants born prematurely

New robotic surgical systems revolutionizing patient care

New MSK research a step toward off-the-shelf CAR T cell therapy for cancer

UTEP professor wins prestigious research award from American Psychological Association

New national study finds homicide and suicide is the #1 cause of maternal death in the U.S.

Women’s pelvic tissue tears during childbirth unstudied, until now

Earth scientists study Sikkim flood in India to help others prepare for similar disasters

Leveraging data to improve health equity and care

Why you shouldn’t scratch an itchy rash: New study explains

Linking citation and retraction data aids in responsible research evaluation

Antibody treatment prevents severe bird flu in monkeys

Polar bear energetic model reveals drivers of polar bear population decline

Socioeconomic and political stability bolstered wild tiger recovery in India

Scratching an itch promotes antibacterial inflammation

Drivers, causes and impacts of the 2023 Sikkim flood in India

Most engineered human cells created for studying disease

Polar bear population decline the direct result of extended ‘energy deficit’ due to lack of food

Lifecycle Journal launches: A new vision for scholarly publishing

Ancient DNA analyses bring to life the 11,000-year intertwined genomic history of sheep and humans

[Press-News.org] Alliance Foundation Trials phase III PATINA study shows promise for patients with HR+, HER2+ metastatic breast cancer
Palbociclib is the first CDK4/6 inhibitor to show benefit in a large phase III trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy